Get the Stockscreener App
2.23
5.08%
-0.13
Boundless Bio Inc stock is traded at $2.23, with a volume of 25,334.
It is down -5.08% in the last 24 hours and down -14.50% over the past month.
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
See More
Previous Close:
$2.36
Open:
$2.35
24h Volume:
25,334
Relative Volume:
0.28
Market Cap:
$49.73M
Revenue:
-
Net Income/Loss:
$-61.06M
P/E Ratio:
-0.1557
EPS:
-14.3261
Net Cash Flow:
$-59.30M
1W Performance:
-2.18%
1M Performance:
-14.50%
6M Performance:
-32.12%
1Y Performance:
+0.00%
1-Day Range:
$2.22
$2.3948
1-Week Range:
$2.1492
$2.54
52-Week Range:
$2.1492
$12.65
Boundless Bio Inc Stock (BOLD) Company Profile
Name
Boundless Bio Inc
Sector
Industry
Phone
(858) 766-9912
Address
9880 CAMPUS POINT DRIVE, SAN DIEGO
Compare BOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BOLD
Boundless Bio Inc
|
2.24 | 49.73M | 0 | -61.06M | -59.30M | -14.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.08 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.65 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.08 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.38 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.36 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Boundless Bio Inc Stock (BOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-22-24 | Initiated | Guggenheim | Buy |
| Apr-22-24 | Initiated | Leerink Partners | Outperform |
| Apr-22-24 | Initiated | Piper Sandler | Overweight |
Boundless Bio Inc Stock (BOLD) Latest News
Francisco Ballester to retire from Sandoz - BioCentury
Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer -February 03, 2025 at 10:00 am EST - Marketscreener.com
Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer - The Manila Times
Beta Bionics targets IPO of up to $120M - BioWorld Online
Neomorph Announces Appointment of Dr. Klaus Wagner, M.D., Ph.D. as Chief Medical Officer - BioSpace
Neomorph Appoints Dr. Klaus Wagner as Chief Medical Officer - citybiz
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online
Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn Situation - Simply Wall St
January Effect Builds Up Momentum: 5 Small-Cap Stocks to Buy - MSN
Terremoto Biosciences Appoints James Christensen, Ph.D., as President and Head of Research & Development - Business Wire
Finance Watch: As Cash Dwindles, Biotechs Cut Costs, Sell Assets, Merge, Assess Options - News & Insights
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
Layoffs Continued Across Biopharma in 2024 - BioSpace
The Escalator: Boundless Bio, Intelliguard, Klick Health and more - MM+M Online
Guggenheim Downgrades Boundless Bio (BOLD) - MSN
Boundless Bio Announces Pipeline and Leadership Updates - The Manila Times
Genesis hires Shifeng Pan as CSO, names Paul Friedman chair - BioCentury
Boundless Bio, Inc. Changes to Management Team - Marketscreener.com
Boundless Bio Won't Advance Cancer Treatment Trial, Executives to Step Down - MarketWatch
Costco Wholesale (COST-Q) QuotePress Release - The Globe and Mail
Vertex Global reports ten IPOs, acquisitions worldwide in 2024 - Tech in Asia
Boundless Bio, Inc. (BOLD) Loses -19.52% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Amgen names Howard Chang head of research and CSO - BioCentury
S&P 500 Consumer Staples [Sector] (SRCS) QuotePress Release - The Globe and Mail
Layoff Tracker: Gilead Sciences Will Lay Off 104 Employees at California HQ - BioSpace
Science Spotlight: How extrachromosomal DNA drives cancer - BioCentury
Extrachromosomal DNA acts as joker for cancer cells - BioWorld Online
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Stanford Scientists Overturn Mendel’s Law With Shocking Cancer Discovery - SciTechDaily
Stanford researchers unveil the key role of extrachromosomal DNA in cancer - News-Medical.Net
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference - The Manila Times
Boundless Bio Prices IPO At $16/Shr - RTTNews
Boundless Bio CFO Jami Rubin steps down By Investing.com - Investing.com Australia
Boundless Bio CFO Jami Rubin Steps Down for Personal Reasons - MarketWatch
Boundless Bio CFO Jami Rubin steps down - Investing.com
Boundless Bio Announces Departure of Chief Financial Officer - The Bakersfield Californian
Ceribell begins trading with upsized IPO - BioWorld Online
Down rounds don’t aid post-IPO performance - BioCentury
Is Boundless Bio (NASDAQ:BOLD) In A Good Position To Invest In Growth? - Yahoo Finance
Varun Dhawan's niece Anjini Dhawan's debut film Binny and Family release postponed - India Today
BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients - GlobeNewswire
Limitless Labs Secures $3M Pre-Seed Funding Led by 1confirmation - iGaming.org
FDA Grants Breakthrough Status to Achondroplasia Drug By Investing.com - Investing.com Canada
Limitless Labs Secures $3M in Pre-Seed Funding Led by 1confirmation - Blockster
A New Prediction Market Raises $3M in Pre-Seed Round Led by 1confirmation - CoinDesk
'Binny And Family' pushed again; to now release on this date - NewsBytes
The War On Drugs On Beyoncé Collaboration: 'It’s Arguably The Coolest Thing I’ve Ever Done' - Dig!
Antibody-drug conjugate found effective against brain metastases in patients with HER2-positive breast cancer - Medical Xpress
Boundless Bio Inc Stock (BOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Boundless Bio Inc Stock (BOLD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CRANDELL KEITH | 10% Owner |
Apr 02 '24 |
Buy |
16.00 |
200,000 |
3,200,000 |
1,181,766 |
| ARCH Venture Fund IX, L.P. | 10% Owner |
Apr 02 '24 |
Buy |
16.00 |
200,000 |
3,200,000 |
1,181,766 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Apr 02 '24 |
Buy |
16.00 |
312,500 |
5,000,000 |
1,884,787 |
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):